- Conference Call and Webcast to Follow at 5:00 p.m. EST/ 2:00 p.m.
PST -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 2, 2015--
Exelixis, Inc. (NASDAQ: EXEL) announced today that its fourth quarter
and full year 2014 financial results will be released on Tuesday,
February 24, 2015 after the markets close. At 5:00 p.m. EST / 2:00 p.m.
PST, Exelixis management will host a conference call to discuss the
results and provide a general business update. The conference call will
be accessible via the Internet from the Company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the Event Calendar page under Investors & Media. Please
connect to the company’s website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
877-546-5020 (domestic) or 857-244-7552 (international) and provide the
conference call passcode 38677626 to join by phone.
A telephone replay will be available until 11:59 p.m. EST on February
26, 2015. Access numbers for the telephone replay are: 888-286-8010
(domestic) and 617-801-6888 (international); the passcode is 64033209. A
webcast replay will also be archived on www.exelixis.com
for one year.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple
receptor tyrosine kinases. Another Exelixis-discovered compound,
cobimetinib, a highly selective inhibitor of MEK, is being evaluated by
Roche and Genentech, Inc. (a member of the Roche Group) in a broad
development program under a collaboration with Exelixis. For more
information, please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
trademarks.
Source: Exelixis, Inc.
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor
Relations and
Corporate Communications
shubbard@exelixis.com
